Abstract
Boron Neutron Capture Therapy is based on the ability of the isotope10B to capture thermal neutrons and to disintegrate instantaneously producing high LET particles. The only neutron beam available in Europe for such a treatment is based at the European High Flux Reactor HFR at Petten (The Netherlands). The European Commission, owners of the reactor, decided that the potential benefit of the facility should be opened to all European citizens and therfore insisted on a multinational approach to perform the first clinical trial in Europe on BNCT. This precondition had to be respected as well as the national laws and regulations. Together with the Dutch authorities actions were undertaken to overcome the obvious legal problems. Furthermore, the clinical trial at Petten takes place in a nuclear research reactor, which apart from being conducted in a non-hospital environment, is per se known to be dangerous. It was therefore of the utmost importance that special attention is given to safety, beyond normal rules, and to the training of staff. In itself, the trial is an unusual Phase I study, introducing a new drug with a new irradiation modality, with really an unknown dose-effect relationship. This trial must follow optimal procedures, which underscore the quality and qualified manner of performance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahlf J, Zurita A, eds. High Flux Reactor (HFR) Petten, Characteristics of the Installation and the Irradiation Facilities. EUR 15151 EN, 1993.
Bohaychuk W, Ball G. Good Clinical Research Practices, An indexed reference to international guidelines and regulations, with practical interpretation. GCRP Publications, January 1994.
Coderre JA. BNCT for malignant glioma using BPA. Proc. 6th Int. Symp. on Neutron Capture Therapy, Kobe, Japan, November 1994; ed. Mishima Y. Plenum Press, New York, 1995.
Gabel D. Approach to Boron Neutron Capture Therapy in Europe: Goals of a European Collaboration on Boron Neutron Capture Therapy. Proc. 2nd. Eur. Particle Accelerator Conf., Nice, 1990.
Gregoire V, Begg AC, Huiskamp H, et al. Selectivity of boron carriers for boron neutron capture therapy: pharmacological studies with borocaptate sodium, L-boronophenylalanine and boric acid in murine tumors. Radiother Oncol 1993;27:46–54.
Hatanaka H, et al. Clinical experience of boron-neutron capture therapy for gliomas — a comparison with conventional chemo-immuno-radiotherapy. In: Hatanaka H (ed.). Boron-Neutron Capture Therapy for Tumors. Niigata, Japan, Nishimura, 1986.
Madoc-Jones H, Zamenhof R, Solares R, et al. Clinical trial begins at MIT/NEMC. Proc. 6th Int. Symp. on Neutron Capture Therapy; Kobe, Japan, November 1994; ed. Mishima Y, Plenum Press, New York. 1995.
Moss RL, Casado J, Ravensberg K, et al. The Completed BNCT Facility at the HFR Petten. 7th Int. Symp. on Neutron Capture Therapy, Zurich. September 1996; ed. Larsson B, Crawford J. Plenum Press, New York, 1997.
Raaijmakers C, Konijnenberg M, Dewit L, et al. Monitoring of blood-10B concentration for boron neutron capture therapy using prompt gamma-ray analysis. Acta Oncologica, 1995;34:517–23.
Sauerwein W, Gabel D, Fankhauser H. Glioma BNCT. Postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility. 1. Phase I clinical trial. EORTC Protocol 11961, March 1997.
Slatkin DN. A history of boron neutron capture therapy of brain tumors. Brain 1993;114.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Sauerwein, W., Moss, R., Rassow, J. et al. Organisation and management of the first clinical trial of BNCT in Europe (EORTC Protocol 11961). Strahlenther Onkol 175 (Suppl 2), 108–111 (1999). https://doi.org/10.1007/BF03038906
Issue Date:
DOI: https://doi.org/10.1007/BF03038906